Medindia

X

Amgen Submits Denosumab Biologics License Application to FDA for the Reduction of Skeletal Related Events in Cancer Patients

Saturday, May 15, 2010 Research News J E 4
Advertisement
Submission Includes Data from Three Pivotal Phase 3 Trials

CONTACT: Amgen, Thousand Oaks

Christine Regan: +1 (805) 447-5476 (media)

Arvind Sood: +1 (805) 447-1060 (investors)

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Steve Siepser, M.D. Joins Distinguished Group of 2...
S
West Haven Firm Expands Biomedical Disposal Progra...